Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer with PSA Screening By Ogkologos - November 4, 2025 285 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ERSPC study Source RELATED ARTICLESMORE FROM AUTHOR Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 MOST POPULAR FOCUS4: Learning from a landmark clinical trial April 25, 2023 A Combination of Amivantamab and Lazertinib Shows Durable Clinical Activity in... October 10, 2023 Anticancer Drugs in the Adjuvant Setting Have Considerable Costs Per Event... July 20, 2022 For Advanced Prostate Cancer, Radiopharmaceutical Improves Survival June 29, 2021 Load more HOT NEWS This Saturday: National Prescription Drug Take-Back Day Mom Who Lost Child Donates Breast Milk To Mom With Cancer Merging the Histologic and Molecular Data Into an Integrated Score Significantly... FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection
